Both nasopharyngeal and tumors and epithelial cancer of topographically different sites of the mouth, laryngopharynx are shown to be associated in many cases with high immunity to virus Epstein-Barr (VEB) antigens. VEB-associated antibody quantitation in patients with laryngeal, laryngopharyngeal, oral and lingual cancer revealed that the malignant process dissemination and the tumor differentiation are related to immune response to VEB antigens: the more advanced is cancer and the poorer is its differentiation, the more pronounced is the immune response.